Advertisement
Survey Series
Institutions
For Advertisers
|
|
||||
|
High-Priced Biotech Drugs: Are They Worth It?
Insurers mull the question, and the answer could affect biotech drug development
Email: Susan Warner - swarner@the-scientist.com The Scientist 2004, 18(23):42
|
||||
|
|
||||
|
Visudyne, a drug for macular degeneration, costs $2,500–4,000 for a course of treatment. Zevalin and Bexxar, used for non-Hodgkins lymphoma, can cost more than $20,000 per dose. While all these drugs can help certain patients, reimbursement has been a problem and some insurers have refused to pay.
|
|
|||||||||
|
|||||||||
|
